ArticleEndocrine2024
Healthcare costs and medical utilization patterns associated with painful and severe painful diabetic peripheral neuropathy.
Article in Endocrine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Virtual Reality-Based Rehabilitation to Improve Mobility and Prevent Falls in Older People With Diabetic Peripheral Neuropathy: Evidence Synthesis and Development of a Geriatric-Specific Framework.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2026Pooled it
- The association between the triglyceride-glucose index and diabetic peripheral neuropathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- The Burden of Small Fiber Neuropathy: Changes in Pain, Costs, and Quality of Life Before and After Diagnosis.Journal of the peripheral nervous system : JPNS · 2026Article
- Endocrinologists' Perspectives on Early Screening for Diabetic Peripheral Neuropathy: A Phenomenological Study in Four Chinese Based Hospitals.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Mechanisms, translational opportunities for diabetic polyneuropathy.Frontiers in endocrinology · 2026Review
- Paeoniflorin as a candidate disease-modifying therapy for diabetic peripheral neuropathy: mechanisms, exposure challenges, and translational priorities.Frontiers in pharmacology · 2026Review
- Estimating the annual cost burden of diabetic peripheral neuropathy in the United States.Endocrine · 2025Article
- Editorial: Diabetes complications in children and adolescents: from low-resource to technology-advanced countries.Frontiers in medicine · 2025Article
- Development and validation of a risk prediction model for painful diabetic peripheral neuropathy in type 2 diabetes mellitus: a multicenter retrospective study.Frontiers in endocrinology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePainful diabetic peripheral neuropathy (DPN) is a common complication in patients with diabetes. It is associated with a poor quality of life and high costs of care. This study investigated the impact of painful DPN on healthcare costs and resource utilization.
methodsThis was a retrospective analysis of administrative claims of adult patients with diabetes (type 1 or 2) from Optum's de-identified Clinformatics® Data Mart Database. Patients were assigned to four cohorts by presence of DPN and pain severity, based on diagnoses and prescription patterns in a one-year baseline. All-cause and diabetes-associated costs were calculated for the year following the index DPN diagnosis. Risk factors associated with presence of severely painful DPN were evaluated.
resultsRelative to those without DPN, patients who had DPN without pain, painful DPN (PDPN), or severe PDPN incurred respective increases of $3,093, $9,349, and $20,887 in average annual all-cause costs. More than half of costs from painful/severe DPN were for prescriptions and inpatient hospitalization. Severe PDPN was associated with elevated odds of diabetic amyotrophy (OR: 8.09; 95% CI: 6.84-9.56), diabetic foot ulcers (OR: 6.54, 95% CI: 6.32-6.76), and loss of mobility (OR: 2.54, 95% CI: 2.48-2.60), among other complications.
conclusionsPainful DPN is associated with higher healthcare costs and resource utilization, and a greater risk of debilitating conditions that limit quality of life. Future research should focus on better treatment options and more aggressive pain management strategies to reduce the negative impacts of DPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.